Skip to main content

Fiscal Wizard · Single-issue tearsheet

BGM / Jun 20, 2026 Run #7203

BGM

BGM Group Ltd.

BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient. The company also provides licorice products, such as Gan Di Xin, a medicine made from raw licorice materials; Qilian Shan licorice extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, an ingredient for medical preparation companies to produce compound licorice oral solutions. In addition, it offers traditional Chinese medicine derivatives products comprising Ahan antibacterial paste that is used to treat refractory chronic skin diseases; heparin products, including heparin sodium preparation, an ingredient for pharmaceutical companies to produce medications used in treating cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings, such as Zhu Xiaochang sausage casings for culinary purposes. Further, the company provides Fertilizer products comprising Xiongguan organic fertilizers to improve crop yield, increase soil's chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers for plant growth. Additionally, it focuses on the AI-driven commercialization of DuXiaoBao platform. BGM Group Ltd. is based in Chengdu, China.

Composite verdict

F 20.0 / 100
Bearish setup · Reversal 3 drivers · 2 gates blocking
  • Fibonacci Retracement
  • Money Flow Index
  • Ichimoku
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 49th of 85 in Drug Manufacturers - Specialty & Generic

rescore-sweep
Technical synthesisRegime: volatile downtrend
Bull 0%Evidence: High · 12 signals100% Bear
Momentum Neutral 41Mean-reversion Bearish 25

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from
Asset value $0.24Earnings power value $0.04Price $0.37

Priced above its no-growth earnings power value ($0.04/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Weak

28.7 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Days Sales Outstanding 97
Free Cash Flow Yield 0
EV/Sales 75
Inventory Turnover 22
P/B 75
EV/EBITDA 25

Technicals Bearish

11.3 / 100

Bearish setup leads (Fibonacci Retracement, Money Flow Index, Commodity Channel Index); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Fibonacci Retracement 19
Money Flow Index 20
Commodity Channel Index 27

Risk Gates

2 blocking 3 caution

2 guards active, 29 signals gated.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Current Ratio Caution

Visual liquidity flag — does not mute signals.

Quick Ratio Caution

Visual liquidity flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for BGM.